Organon, which was spun out from Merck in 2021, has a portfolio of more than 60 medicines across a range of therapeutic areas, led by its established products division. Featured are such drugs as asthma medication Singulair and cholesterol drug Azotet, which accounts for two-thirds of its $6.3 billion in revenues. This is supported by its women’s health division (25% of revenues) and its biosimilars division. Its range of products produce strong cash flows that support innovation and future growth opportunities. It employs 10,000 people and is headquartered in Jersey City, NJ.